Brokerage Report: CLSA upgrades Dr. Lal Pathlabs, sees 14% upside; CMP 12% below target

CLSA has upgraded its rating on Dr. Lal Pathlabs to ‘Outperform’ and raised its target price to ₹3,240, indicating a 14% potential upside from the current market price (CMP) of ₹2,847.85.

Key highlights:

Advertisement

  • Continuous improvement in volume growth, which bottomed out in FY24, coupled with steady pricing trends.
  • The stock is currently down 22% from its previous high, which CLSA believes is overdone.
  • Dr. Lal Pathlabs now trades at a discount to its peers, compared to the premium it commanded earlier.

At its CMP of ₹2,847.85, the stock is trading approximately 12% below CLSA’s revised target of ₹3,240.

Disclaimer: This article is for informational purposes only and does not constitute financial advice.